Social

Our proprietary GPCR-targeted structure-based drug discovery NxWave™ platform has enabled us to develop small molecules, peptides and antigens for antibody discovery. To date, we have leveraged our technologies and expertise to create a pipeline of drug candidates targeting GPCRs that we believe have potential to become first-in-class or best-in-class medicines in therapeutic areas such as neurology, immunology and gastroenterology diseases.

Alongside our in-house programs, we are collaborating with world leading partners, including major biopharmaceutical companies, emerging technology companies and innovative venture capital funds to address diseases with high unmet medical needs, and for which there are no suitable treatments currently available.

Nxera Pharma takes its responsibility to work towards providing access to medicines and healthcare to all people around the world seriously. The company provides access to some of its scientific discoveries in order that others may use them for their own research to improve the understanding of diseases and accelerate the development of new medicines. For example, our scientists have solved over 390 GPCR structures from more than 50 different GCPR targets using our innovative NxStaR^® technology, with many of these released into the scientific community.

Nxera Pharma actively seeks to contribute to the development and enhancement of our communities as well as to the broader society. In 2023, we made charitable donations amounting to £16,891.62 to the following organisations and initiatives:

The promotion of diversity and inclusion and the creation of a collaborative working environment are core pillars of Nxera Pharma’s vision, as pioneers from Japan, to lead the new era of biopharma and medicine, innovating for both Japanese patients and the world. As a global company, Nxera Pharma’s Board of Directors comprise 33% non-Japanese nationals (including our CEO) and 54% of our global workforce are non-Japanese nationals (Japanese – 46%, British – 32%, Rest of the World 22%). We are also proud to have a diverse workforce comprising 46% female colleagues, including 49% new female hires in 2023.

Nxera Pharma believes meaningful progress has been made to promote diversity and pay equity in 2023 and will continue to make year-on-year progress across the organization.

We are committed to supporting our colleagues reaching their full potential by providing opportunities for growth and development, and through rewarding performance and leadership. Nxera Pharma ensures that each employee has the requisite and up-to-date skills training for their role, facilitated through regular personal development discussions and tailored training programs based on our training matrix. The company also supports individuals attaining further qualifications or certifications within their field of expertise. We are committed to scientific talent development through internal secondments and regular conference attendance.